Bethanechol
![Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’](http://data.docslib.org/img/264x/0e21d1edc8e809789d0c6b5f7f204d19.webp)
Top View
- Neurologic Urinary and Faecal Incontinence
- Urinary Incontinence
- Bethanechol Chloride in Neurogenic Bladder Dysfunction
- Urinary Frequency Tom Kincer, MD Program Director Clinical Professor of Medicine Montgomery Family Medicine Residency
- RX Formulary E1/E4 Drug List PBCBSAK
- End of Life Care: Talking About Hospice
- Therapeutic Class Overview Urinary Antispasmodics
- Oxybutynin Hydrochloride 3Mg Tablets
- Product Monograph
- Buprenorphine–Induced Urinary Hesitancy
- A Phase 4, Double-Blind, Randomized, Placebo-Controlled
- Technologies for Managing Urinary Incontinence
- Appendix. Common Proprietary Equivalents of Drugs Mentioned in the Text
- Remedies for Urinary Diseases Comprising Lpa Receptor Controlling Agents
- Muscarinic Acetylcholine Receptor Agonists and Antagonists Regulate Yeast to Hyphal Form Transition in Candida Albicans
- Effects of Pilocarpine, a Muscarinic Receptor Agonist, on Contraction of the Pig and Human Urinary Bladder
- Nursing Process Focus: Patients Receiving Bethanechol (Urecholine)
- (12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr